Does JAGX pay a dividend and is it safe?

Jaguar Health Inc. (JAGX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / JAGX / dividends

HIND (29) BOLT (37) BIVI (32) KTTA (40) ⌘ Pro Terminal →

Jaguar Health Inc. (JAGX) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.88 -45.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.81

Jaguar Health Inc. (JAGX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JAGX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JAGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.88 (-45.43% 1D, market cap $12.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JAGX ranks #872 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JAGX compare to HIND and BOLT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and BOLT (Bolt Biotherapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while JAGX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JAGX?

▼

Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.81 (-8.37%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JAGX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY JAGX SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.16-36.8% Next Q

Q2 (-2Q)

Grade E$2.63-14.8% Next Q

Q3 (-1Q)

Grade E$2.24-60.7% Next Q

Current

Grade E$0.88-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JAGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JAGX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.00) and Max Pain ($0.92) forces dealer call-delta covering toward $1,157.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JAGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “JAGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JAGX)

✓Walkthrough of JAGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JAGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.19%▼ DESCENDING CHANNEL

2026-11-03O $2.04H $2.04L $0.88C $0.88VOL 383.6K

RES: $39.15SUP: $-7.73SMA50: $6.00SMA200: $114.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JAGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JAGX Butterfly Map → + Track JAGX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JAGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JAGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JAGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JAGX)

Health Care Rank #872 of 1016 ⚔️ HIND vs JAGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JAGX vs. HIND, BOLT, BIVI, KTTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Jaguar Health Inc. (JAGX) ranks #872 by composite RQD confidence (28/100, grade E) and #870 by equity capitalization ($12.6M). Within this direct 5-issuer industry benchmark cohort, JAGX leads on earnings valuation at N/A trailing P/E, while JAGX leads on capital efficiency and profitability with -35.0% ROIC and 67.2% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JAGX at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JAGX ACTIVE Jaguar Health Inc.	E	28/100	—	67.2%	-35.0%	-45.43%	$12.6M	Benchmark Subject
HIND Vyome Holdings Inc.	E	29/100	—	68.4%	-35.0%	-2.22%	$12.6M	/hind-vs-jagx →
BOLT Bolt Biotherapeutics Inc.	D-	37/100	—	—	-35.0%	-5.31%	$12.7M	/bolt-vs-jagx →
BIVI BioVie Inc. (Class A)	E	32/100	—	—	-35.0%	-4.20%	$12.4M	/bivi-vs-jagx →
KTTA Pasithea Therapeutics Corp.	D-	40/100	—	—	-35.0%	-0.59%	$12.4M	/ktta-vs-jagx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585608

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jaguar Health Inc. (JAGX) reported GAAP revenue of $11.5M (-1.5% vs. FY2024 revenue of $11.7M , and +17.9% cumulative change since FY2023) , GAAP net income of -$54.0K, operating cash flow of -$23.7M, and free cash flow of -$23.7M (+19.4% YoY). On the balance sheet, JAGX closed FY2025 with $38.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$11.5M	-$54.0K	-$23.7M	-$23.7M	$38.3M	—
FY2024 (FY)	2024-12-31	$11.7M	-$39.3K	-$29.4M	-$29.4M	$53.4M	—
FY2023 (FY)	2023-12-31	$9.8M	-$41.9K	-$33.2M	-$33.2M	—	—

3. JAGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JAGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does JAGX compare to HIND and BOLT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for JAGX?

Where is JAGX trading relative to its 50-day, 200-day, and 52-week technical levels?

JAGX last traded at $0.88 (-45.43% on volume of 2,204,041 shares), positioning the stock -85.33% below its 50-day simple moving average ($6.00) and -99.23% below its 200-day simple moving average ($114.36). Across its 52-week range of $1.60 to $1,102.50, JAGX sits at the 0.0% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

Direct Sub-Reports: JAGX RQD Cockpit JAGX 12M Forecast JAGX Earnings & Move JAGX Dividends & DRIP JAGX Insiders & 13F JAGX Whale Options JAGX Profit Sankey JAGX News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

JAGX — Jaguar Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Jaguar Health Inc. (JAGX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.88 (-45.43% 1D, market capitalization $12.6M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 67.2%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Jaguar Health Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The sources do not describe its specific products, customers, or revenue model beyond the sector classification and the catalyst headline referencing a crofelemer intestinal failure program and an MVID NDA filing target. FY 2025 revenue was $11.5M against an operating loss of -$45.9M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jaguar Health Inc. (JAGX) reported $11.5M in annual revenue (up from $11.7M in FY2024, -1.5% YoY) and -$54.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.8M revenue, -$41.9K net income) through FY2025, JAGX scaled operating cash flow to -$23.7M and free cash flow to -$23.7M, backed by $38.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.60 – $1,102.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlations beyond the Beta of 1.0 are — The second-order item to watch is the interaction between the negative free cash flow reported in each period and the preferred-share special dividend, since dilution or capital-structure changes can alter the funding need implied by the reported cash balance.

Key Question #1: Can JAGX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $11.5M and free cash flow of -$23.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is JAGX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

JAGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Jaguar Health Inc. (JAGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JAGX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances

Yahoo Finance report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 23h ago

Jaguar Health (JAGX) Declares Special Stock Dividend of Series R Convertible Preferred Shares

GuruFocus report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Jaguar Health, Inc. (JAGX) Sets Record Date for Special Stock Dividend

TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Jaguar Health Stock Price Forecast. Should You Buy JAGX?

StockInvest.us report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Jaguar Health (JAGX) Stock Forecast & Analyst Ratings

Moomoo report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ACCESS Newswire • 1d ago

Jaguar Health Provides Update Regarding Special Stock Dividend

ACCESS Newswire report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An infant with a rare intestinal condition needed about 15% less IV support within weeks.

Stock Titan report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Jaguar Health (JAGX) Stock Climbs Over 34% After-Hours: What's Going On?

TradingView report covering Jaguar Health Inc. (JAGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JAGX Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JAGX 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.04 (+25.9%)

📌 Pinned Debate

JAGX (E • RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.62

Long JAGX at $1.62 targeting $2.04. JAGX (E • RQD 28/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.62. Institutional whale score is 3/20 and the risk/reward vs. the $1.60 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $1.62 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.23 (-24.1%)

Spot @ $1.62

Negative free cash flow of -$23.7M in FY 2025 against only $1.0M of reported cash, with a Piotroski F-Score of 1/9, signals a funding g

Here is the bear case nobody on the bull side wants to address on JAGX: Negative free cash flow of -$23.7M in FY 2025 against only $1.0M of reported cash, with a Piotroski F-Score of 1/9, signals a funding gap.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.